Latest Technology News

Archer Materials has achieved a significant milestone by integrating its graphene-based sensors with silicon readout circuitry, paving the way for a compact, at-home potassium testing device aimed at chronic kidney disease management.

Nimy Resources has successfully completed Phase 2 drilling at its Block 3 Gallium prospect in Western Australia, intercepting key host rock in 9 of 11 holes. Phase 3 drilling has now commenced to explore extensions beyond the original target.

Invion Limited reports no adverse events and early lesion reduction in its Phase I/II non-melanoma skin cancer trial, advancing to dose optimization.

Aroa Biosurgery has reported FY25 results that exceed revenue guidance and deliver a positive normalised EBITDA, setting the stage for ambitious growth and reimbursement expansion in FY26.

Aroa Biosurgery has reported a robust 23% revenue increase in FY25, achieving profitability and positive cash flow, setting the stage for continued growth in FY26.

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.

Gentrack Group has committed an additional AUD4.5 million to Amber’s AUD45 million funding round, reinforcing their strategic partnership to accelerate the global rollout of smart energy technologies.

ikeGPS Group Limited (IKE) reported a robust FY25 with 19% revenue growth driven by subscription gains and improved margins, setting the stage for EBITDA break-even in FY26 H2 amid strong North American market demand.

ikeGPS Limited has posted a 19.2% increase in revenue for the year ending March 2025, reaching NZD 25.155 million, yet the company recorded a significant net loss of NZD 16.338 million with no dividend declared.

HITIQ has secured a three-year deal with AFL Barwon to promote its PROTEQT smart mouthguard across regional Victoria, enhancing concussion management in community sports.

Talius Group Limited has secured shareholder approval to consolidate its shares on a 10-for-1 basis, aiming to better align its capital structure with industry peers. The move affects all ordinary shares and performance rights, effective June 4, 2025.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.